Triiodothyronine sulfate (T3S) is rapidly deiodinated by the propylthiouracil (PTU)-sensitive type I deiodinase. Here we examined the effects of PTU on plasma T3S levels in rats after intravenous administration of radiolabeled T3 or T3S. Sephadex LH-20 chromatography and high-performance liquid chromatography were used to quantify conjugated and nonconjugated iodothyronines, and iodide was measured as the TCA-soluble radioactivity. In control rats, radioiodide was the main metabolite of both T3 and T3S. Plasma T3S was cleared more rapidly than plasma T3 despite increased binding to plasma proteins. PTU reduced plasma iodide levels by 66 and 78% after T3 and T3S, respectively, and decreased plasma clearance of T3S by 81%. However, PTU had no effect on plasma T3 clearance but increased plasma T3S from injected T3 4.2 times. Biliary excretion of injected T3S was less than 20% in normal rats, in contrast to 70% within 4 h in PTU-treated rats. In conclusion, T3S is an important intermediate in the in vivo metabolism of T3 in rats and accumulates in plasma if type I deiodination is inhibited.
Introduction
Stepwise monodeiodination plays a central role in the metabolism of thyroid hormone in peripheral organs such as liver and kidney (1, 2) . After the bioactivation of thyroxine (T4)' to 3,3',5-triiodothyronine (T3) by outer ring deiodination, T3 is further converted to biologically inactive iodothyronines by successive deiodination in inner and outer rings (3) . In humans, metabolic pathways other than deiodination seem equally important for the inactivation and elimination of T3 (1) . Conjugates ofT3 with glucuronic acid or sulfate have been detected by Bollman and Flock (4) in bile and urine ofrats and dogs.
In vitro, enzyme kinetic studies with liver type I deiodinase have shown that, in contrast to T3 itself, T3 sulfate (T3S) is rapidly deiodinated in the inner ring (5) . The 3,3'-diiodothyronine sulfate (T2S) produced is also a much better substrate for outer ring deiodination than nonconjugated T2 (5, 6) . Under normal conditions primary cultures of rat hepatocytes metabolize added ['25I]T3 to iodide and T3 glucuronide (T3G). Addition of the type I deiodinase inhibitor 6-propyl-2-thiouracil (PTU) results in accumulation ofthe T3S intermediate without affecting T3 clearance (6) . Iodide production is also decresed in sulfate-deplete cells or by inhibitors ofphenol sulfotransferase, but under these conditions T3 clearance is diminished as well (6) . It was subsequently shown that PTU treatment resulted in a fivefold increase in biliary T3S after administration of['25IJT3 to rats without affecting excretion of T3G2 (7) . Therefore, sulfation and subsequent deiodination is an important metabolic pathway for T3 in rat liver. To further investigate the physiological relevance of this pathway we analyzed plasma T3S in rats with impaired type I deiodinase activity. [125I]T3 or ['25I]T3S in 500 1l 0.01 M NaOH in saline was injected intravenously (t = 0). Blood samples (0.75 ml) were taken from the tail vein at 0.5, 1, and 2 h, and after cervical dislocation at 4 h the animals were bled by heart puncture.
Methods
Biliary excretion of intravenously injected [125I]T3S was studied as follows. The biliary duct ofpentobarbital-anesthetized rats (200 g BW) was cannulated2 and the animals were injected with PTU or vehicle followed by 10 MCi ['25I]T3S as described above. Blood samples (0.3 ml) were obtained in heparinized vials after 0.5, 1, 2, and 4 h, and bile was collected in 10-20 min periods.
In a parallel experiment PTU was administered 2 h before the animals were anesthetized whereupon the bile duct was cannulated and [1251J]T3 injected, i.e., 2.5 h after PTU. Bile and plasma were collected until 4 h after T3 injection. Analysis of samples. Serum and bile were kept at -20'C until further analysis. Plasma '25Iwas measured as trichloroacetic acid (TCA)-soluble radioactivity. For this purpose, 50-100 u serum was mixed with 10% (wt/vol) ice-cold TCA to a final volume of 500 gl. After 10 min at00C, mixtures were centrifuged and radioactivity was determined in the supernatant. Radioiodide in bile was estimated similarly by addition of 100 ul pooled human serum to 10-25 id bile followed by 400 ,d 10% TCA. > 95% of T3 or T3S added to plasma or bile was precipitated by TCA while on average 97% of added '251remained in solution.
For analysis of other plasma metabolites, mixtures were prepared consisting of 250 gl serum, 500 M1 0.2 M HCl, and 250 Ml ethanol. These were applied to small Sephadex LH-20 columns (bed vol, 1.3 ml) equilibrated in 0.1 M HCL. After rinsing the columns with 0.1 M HCl, conjugated and nonconjugated iodothyronines were eluted successively with 20% ethanol in water and 0.1 M ammonia in ethanol.
Fractions ofI ml were collected and counted for radioactivity. Recovery of T3S and T3 added to rat plasma amounted to 91 and 94%, respectively. For further identification of the isolated products by high-performance liquid chromatography (HPLC), peak fractions of corresponding time points were combined within each experimental group. The conjugate pool was lyophylized and the iodothyronine pool was evaporated under a stream of nitrogen at 50°C. lodothyronines and their conjugates were isolated from the 4-h plasma samples by solid-phase extraction (SPE) for subsequent analysis by HPLC. In short, 500 Ml serum was mixed with an equal volume 0.25 M NaOH and applied to a Ci8-SPE column (500 mg, J. T. Baker Chemical Co., Phillipsburg, NJ). Columns were washed successively with 2 X I ml of each 0.1 M NaOH, H20, 0.1 M HC1, and H20 before elution of both conjugates and iodothyronines with I ml methanol. The recovery of T3 and T3S added to rat plasma was 90 and 96%, respectively. HPLC analysis. Reversed-phase HPLC was done on a 10 X 0.3-cm Chromspher C18 analytical column in combination with a 10 X 2.1mm guard column (Chrompack International BV, Middelburg, Netherlands). Elution was performed with a 20-min gradient of 18-40% acetonitrile in 0.02 M ammonium acetate (pH 4). Solvent flow was 0.8 ml/min and fractions of 0.5 min were collected. A nonlinear gradient (No. 7) as programmed by the automated gradient controller (model 680, Waters Associates, Milford, MA) was used. The residues of the plasma extracts were dissolved in mobile phase and the gradient was started at the time of injection. Retention times of possible products were determined using synthetic and biosynthetic reference compounds (9) . HPLC analysis of biliary products was performed on 5-25-Ad aliquots of bile diluted with 4 vol of mobile phase. Analysis, especially of glucuronide conjugates in bile, was more accurate if a 25-min gradient of 16-40% acetonitrile was used.
Results
Identification ofmetabolites. All metabolites of interest were well separated using reversed-phase HPLC, and a typical chromatogram is shown in Fig. 1 . Neither serum residues nor small amounts of bile in the HPLC samples affected the elution profile seen with pure tracers.
Analysis ofplasma T3 and T3S metabolites. LH-20 fractions eluted as T3 or T3S on HPLC. Therefore, plasma radioactivity other than iodide as fractionated on LH-20 consisted predominantly of T3S or T3. Nonconjugated T2 was never observed, but T2S was detected in T3-injected rats where it comprised on average 10% of the radioactivity in the Sephadex LH-20 (Fig. 2 ). Corresponding conjugate (solid line) or iodothyronine (dashed line) fractions were pooled for each experimental group and further analyzed by HPLC (Fig. 1) . Chromatograms represent -49, 80, 25, and 78% of total plasma radioactivity due to removal of mainly 125Iby LH-20 from samples A, B, C, and D, respectively. Note the smaller scale in C, where the first peak represents only 2% of plasma iodide. conjugate fraction. After T3S injection, plasma T3 was negligible in control rats and represented < 4% of plasma radioactivity in PTU-treated rats. Neither T4 nor the glucuronides of T3 and T2 were observed in any of the samples. HPLC of solidphase extracts of 4-h plasma samples were in close agreement with analysis of the LH-20 fractions. > 95% of radioiodide added to plasma eluted in the first five fractions of the LH-20 chromatography. However, coelution of some protein-bound radioactivity or unknown metabolites could not be excluded. Therefore, accurate measurements of free iodide in plasma was performed by TCA precipitation. The radioactivity in the HCO fractions after LH-20 correlated well with the amount of TCA-soluble radioactivity as shown by linear regression analysis. For the means of these parameters in the different experimental groups the following function was derived: y (HC1) = 1.3 x (TCA) + 0.1 (r = 0.997, n = 16) with x and y expressed as percentage of plasma radioactivity. Apparently, the LH-20 method overestimated plasma iodide levels and was not used for calculation of the results.
Effect ofPTU on the metabolism of T3 and T3S. Results of the measurement of plasma T3 and T3S by Sephadex LH-20 and of iodide by TCA precipitation are summarized in Fig. 4 . Radioiodide was the main plasma metabolite of both T3 and T3S in control rats. PTU did not affect plasma T3 clearance but decreased T3S clearance by 81%, as estimated from the area Sephadex LH-20 fractionation (Fig. 2 ). In [(25I]T3-injected rats roughly 10% of the radioactivity in the "T3S fraction" consisted of T2S. Radioactivity of compounds is expressed as mean percent dose per milliliter plasma (±SD unless smaller than symbol) and plotted as a function of time after tracer injection. Total amount of plasma radioactivity decreased over the 4-h period from 0.52±0.07 to 0.33±0.05 after T3 (n = 5), from 0.50±0.08 to 0.26±0.04 after T3 + PTU (n = 5), from 0.68±0.04 to 0.29±0.04 after T3S (n = 4), and from 0.82±0.03 to 0.17±0.03 after T3S + PTU (n = 4). Except for plasma disappearance of T3, differences between controls and PTU rats were highly significant (P < 0.001) as estimated by Student's unpaired t test.
under the plasma T3S concentration curve. In control rats clearance of plasma T3S was faster than that of T3, but the reverse was true after PTU treatment. The administration of PTU diminished plasma iodide levels by 60-71% after T3 injection and by 74-80% after T3S. PTU increased plasma T3S 2.7 times at 0.5 h to 7.5 times at 4 h after T3 injection, with an average of 4.2 times. This resulted in T3S being the major radioactive compound in plasma from 2 h after T3 injection onwards. Similar results were obtained in rats with bile cannules, where T3 injection was delayed until 2.5 h as opposed to 0.5 h after PTU administration.
Biliary clearance of T3S (Fig. 5 ). In control rats < 20% of radioactivity injected as T3S was excreted in the bile, occurring predominantly during the first 30 min. In PTU-treated rats biliary excretion was greatly increased up to 70% of the dose after 4 h. HPLC analysis demonstrated that T3S was the only 760 M. Rutgers, F. Bonthuis, W W. de Herder, and T. J. Visser significant compound in bile. Iodide was excreted only in bile ofcontrol rats and amounted to 2.5% ofthe administered dose. T2S was observed in bile of PTU-treated rats but accounted for < 3% of the biliary radioactivity. In these cannulated rats distribution of plasma radioactivity was the same as in intact rats and pretreatment with PTU resulted in a 57-84% decrease in plasma iodide over the 4-h period. Plasmafree T3 and T3Sfractions. The non-protein-bound fractions of T3 and T3S in rat plasma were determined in duplicate by equilibrium dialysis. The free fraction was 0.35±0.03 (mean±SD, n = 6) for T3 and 0.20±0.03 (n = 4) for T3S, and both were unaffected by 1 mM PTU.
Discussion
The role of conjugation in the metabolism of thyroid hormone, especially in humans, has received little attention in the literature. Extensive conjugation of thyroid hormone has been demonstrated in experimental animals. Bollman and Flock (4) have identified glucuronides as the main excretory products of various iodothyronines in the bile of normal rats. However, the sum of T2S and T3S excreted in bile equalled or exceeded that of T3G after administration of T3 to dogs (10, 1 1). Studying the biliary clearance of T4 in rats, Flock and Bollman (12) observed that thiouracil treatment increased the excretion of an acid-hydrolyzable T4 conjugate which perhaps represented T4 sulfate (8) . A similar effect was also observed with butyl 4-hydroxy-3,5-diiodobenzoate, which is also an inhibitor of type I deiodinase activity. Treatment of rats with this compound in addition to labeled T3 or T4 led to a far greater increase in biliary sulfates compared with glucuronides (13).
Roche et al. (14) reported on the presence of radioactive T3S in bile and plasma ofthyroidectomized rats after injection with labeled T3. We previously observed an increase in biliary T3S from exogenous T3 in rats treated with PTU2 (7) . We have now shown that the same treatment results in a marked accu-mulation of plasma T3S. In retrospect, it is possible to explain the findings of Roche et al. (14) as it has become evident that hypothyroidism in rats is associated with an impaired hepatic deiodinase activity (15) . Although these investigators did not study euthyroid rats, their results agree with ours, indicating that T3S accumulates if subsequent deiodination is inhibited.
In control rats, injected T3S is metabolized more rapidly than T3 although it binds with higher affinity to plasma proteins, and only radioiodide was detected as a metabolite. Similar rapid deiodinative clearance of T3S in humans has been reported recently (16) . Clearance of T3S is strongly inhibited by PTU, indicating that it is largely metabolized by type I deiodination. In contrast, T3 disposition is not affected by PTU as also observed by others (17) , illustrating that direct inner ring deiodination of T3 by the liver type I deiodinase is a negligible metabolic pathway. The slower metabolic clearance rate ofT3S compared with T3 in PTU-treated rats has also been observed in thyroidectomized rats (18) and entirely explains the increase in plasma T3S from exogenous T3. The plasma T3S levels thus obtained underscore the importance of sulfation as metabolic pathway of T3.
In PTU-treated rats plasma T3S is cleared predominantly by biliary excretion. It is possible, therefore, that also after injection of T3 most T3S in bile is derived from plasma T3S. Although T3 is sulfated and glucuronidated in rat hepatocytes (6), it is not excluded that part of plasma T3S originates by sulfation of T3 in other tissues as was observed in hepatectomized dogs (4, 10) .
Plasma T2S was observed in both normal and PTU-treated rats after injection of T3 but not after T3S. Therefore, it is probably derived from sulfation of T2 that is produced by PTU-insensitive (type III) inner ring deiodination of T3 (2). This would also explain the marked biliary T2S excretion after T3 injection to PTU-treated rats2 (7) in contrast to the negligible amounts of T2S in bile of T3S-injected rats (this study).
In conclusion, the present study of plasma T3S formation in T3-injected rats extends previous observations in bile, indicating that sulfation is an important pathway of T3 metabolism in rats. However, unless subsequent type I deiodination of the conjugate is prevented, little T3S is observed in both body fluids. The finding of significant amounts of T3S in rat plasma opens the perspectives of studying the importance of T3 sulfation in humans. The recent development ofa radioimmunoassay for T3S in our laboratory should facilitate such investigations (19) . The findings that in human liver T3 is a substrate for phenol sulfotransferase (20) and that T3S is rapidly deiodinated (21) suggest that successive sulfation and deiodination of T3 indeed occurs in humans.
